Sarepta Therapeutics Restructuring

Order byBest matchMost fresh

Sarepta, Restructuring Plan

Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan

Shares of struggling drug developer Sarepta Therapeutics ( SRPT) skyrocketed nearly 40% in extended trading Wednesday after the company unveiled a major restructuring plan.

· 4d · on MSN

Sarepta Therapeutics rises after restructuring, pipeline focus

· 4d · on MSN

Sarepta Therapeutics to Restructure, Lay Off 500 Workers

· 1d

Sarepta tells FDA it won’t halt shipments despite patient deaths

The FDA said in a statement Friday night that officials met with Sarepta and requested it suspend all sales but “the company refused to do so.”

· 2d

Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

· 1d

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

Hoodline7h

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

2don MSN

Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial

Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for one of its medications.

Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its outlook. Click for my SRPT stock update.

Business Wire4d

Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan

GEN - Genetic Engineering and Biotechnology News3d

Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the deaths of two Duchenne muscular dystrophy (DMD) patients following treatment with the marketed gene therapy Elevidys® (delandistrogene moxeparvovec-rokl).